Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 28, 2023 09:30 ET | Source: Kineta, Inc.

Kineta Announces Participation at October Investor Conferences

SEATTLE, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer...
September 25, 2023 09:30 ET | Source: Kineta, Inc.

Kineta to Present New Preclinical Data on Lead Anti-CD27 Agonist Antibody at AACR Special Conference on Tumor Immunology and Immunotherapy

SEATTLE, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer...
September 18, 2023 09:30 ET | Source: Kineta, Inc.

Kineta Announces New Research Agreement to Evaluate VISTA Biomarker Expression

SEATTLE, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer...
August 31, 2023 09:30 ET | Source: Kineta, Inc.

Kineta to Participate in Upcoming Investor Conferences

SEATTLE, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer...
August 11, 2023 16:01 ET | Source: Kineta, Inc.

Kineta Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Initial Clinical Data Readout from Ongoing Phase 1/2 Study of VISTA-Targeting KVA12123 in Advanced Solid Tumors Anticipated by End of 2023 Received $5 Million Research and Development Collaboration...
June 29, 2023 06:30 ET | Source: Kineta, Inc.

Kineta to Receive $5 Million Milestone Payment from Merck

SEATTLE, June 29, 2023 (GLOBE NEWSWIRE) -- (June 29, 2023) Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that...
June 28, 2023 06:30 ET | Source: Kineta, Inc.

Kineta Expands Board of Directors with Biotech Industry Leaders Kim Drapkin and Scott Dylla

SEATTLE, June 28, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer...
May 24, 2023 06:30 ET | Source: Kineta, Inc.

Kineta Set to Join Russell Microcap® Index

SEATTLE, May 24, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune...
May 23, 2023 06:30 ET | Source: Kineta, Inc.

Kineta to Present at Jefferies Healthcare Conference

SEATTLE, May 23, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune...
May 11, 2023 17:20 ET | Source: Kineta, Inc.

Kineta Reports First Quarter 2023 Financial Results and Provides Corporate Update

Dosed First Patient in Phase 1/2 Clinical Study of VISTA-Targeting KVA12123 in Advanced Solid Tumors Initial KVA12123 Clinical Data Readout Anticipated by End of 2023 Closed $6 Million Registered...